Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 14/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 11/20 | 0.67 |
| ▸ | SCN1A | P35498 | 1/20 | 0.60 |
| ▸ | SCN5A | Q14524 | 8/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20167089 | 1.00 | SCN9A (0.67) | SCN9ACYP3A4SCN1ASCN5A | |
| SCHEMBL30626723 | 0.87 | SCN9A (0.69) | SCN9ACYP3A4SCN1ASCN5A | |
| SCHEMBL20167423 | 0.87 | SCN9A (0.69) | SCN9ACYP3A4SCN1ASCN5A | |
| SCHEMBL18983110 | 0.84 | SCN9A (0.67) | SCN9ACYP3A4SCN1ASCN5A | |
| SCHEMBL26761547 | 0.84 | SCN9A (0.45) | SCN9ACYP3A4SCN1ASCN5A | |
| SCHEMBL30626771 | 0.84 | SCN9A (0.65) | SCN9ACYP3A4SCN1ASCN5A | |
| SCHEMBL20167074 | 0.84 | SCN9A (0.65) | SCN9ACYP3A4SCN1ASCN5A | |
| SCHEMBL18983125 | 0.83 | SCN9A (0.64) | SCN9ACYP3A4SCN1ASCN5A | |
| SCHEMBL20167403 | 0.83 | SCN9A (0.65) | SCN9ACYP3A4SCN1ASCN5A | |
| SCHEMBL30626724 | 0.83 | SCN9A (0.65) | SCN9ACYP3A4SCN1ASCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10968210-B2 | Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels | MERCK SHARP & DOHME CORP. (US) | 2021-04-06 | — | — | US | disclosed |
| US-20200131167-A1 | DIAMINO-ALKYLAMINO-LINKED ARYLSULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | MERCK SHARP & DOHME CORP. (US) | 2020-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10968210-B2 | Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels | TRPV1, SCN1A, SCN7A | SCN9A 5/4885CYP3A4 3449/4885SCN1A 2/4885 |
| US-20200131167-A1 | DIAMINO-ALKYLAMINO-LINKED ARYLSULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | TRPV1, SCN1A, SCN7A | SCN9A 5/4885CYP3A4 3449/4885SCN1A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.